Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune disease that still lacks any dedicated medicines.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Astellas Pharma has become the latest company to pull back from a potential treatment for Sjögren’s syndrome, an autoimmune disease that still lacks any dedicated medicines.